NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$66.11 +0.78 (+1.19 %)
(As of 12/11/2018 01:52 AM ET)
Previous Close$65.33
Today's Range$64.59 - $66.15
52-Week Range$49.22 - $83.49
Volume168,548 shs
Average Volume178,557 shs
Market Capitalization$1.84 billion
P/E Ratio34.98
Dividend Yield1.20%
Beta0.64
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CNMD
Previous Symbol
CUSIP20741010
Phone315-797-8375

Debt

Debt-to-Equity Ratio0.68
Current Ratio2.20
Quick Ratio1.27

Price-To-Earnings

Trailing P/E Ratio34.98
Forward P/E Ratio30.47
P/E Growth2.62

Sales & Book Value

Annual Sales$796.39 million
Price / Sales2.34
Cash Flow$4.0509 per share
Price / Cash Flow16.32
Book Value$22.60 per share
Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)$1.89
Net Income$55.48 million
Net Margins8.56%
Return on Equity9.51%
Return on Assets4.51%

Miscellaneous

Employees3,100
Outstanding Shares28,130,000
Market Cap$1.84 billion
OptionableOptionable

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Friday, November 9th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Thursday, December 13th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) posted its earnings results on Thursday, November, 1st. The medical technology company reported $0.46 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.45 by $0.01. The medical technology company earned $202.30 million during the quarter, compared to the consensus estimate of $198.51 million. CONMED had a net margin of 8.56% and a return on equity of 9.51%. The company's quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business earned $0.42 EPS. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.17. CONMED also updated its FY 2018 guidance to $2.15-2.20 EPS.

What price target have analysts set for CNMD?

3 Wall Street analysts have issued 12 month price targets for CONMED's stock. Their forecasts range from $78.00 to $83.00. On average, they anticipate CONMED's stock price to reach $80.6667 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Price Targets for CONMED.

What is the consensus analysts' recommendation for CONMED?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Has CONMED been receiving favorable news coverage?

News articles about CNMD stock have trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CONMED earned a news impact score of 1.2 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the company's share price in the immediate future.

Who are some of CONMED's key competitors?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 54)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 52)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 43)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 43)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 49)

Who are CONMED's major shareholders?

CONMED's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.34%), Vanguard Group Inc. (9.48%), Dimensional Fund Advisors LP (6.24%), Capital Research Global Investors (6.11%), Scopia Capital Management LP (4.28%) and Macquarie Group Ltd. (2.81%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Alliancebernstein L.P., Fisher Asset Management LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

Which institutional investors are buying CONMED stock?

CNMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Capital Research Global Investors, Morgan Stanley, O Shaughnessy Asset Management LLC, Putnam Investments LLC, American Century Companies Inc. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $66.11.

How big of a company is CONMED?

CONMED has a market capitalization of $1.84 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is http://www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (NASDAQ CNMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel